EUVIMEDEUVIMED entdecken
Crossref

Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling

Shan Lu, Chenxi Cao, Wenjia Zhang, Jiayi Li, Jingli Yang, Zisheng Huang, Zhijun Wu, Baitao Liu, Hongjie Huang, Haijun Wang, Yongjian Wang, Dingge Liu und 9 weitere

Science China Life Sciences · 2025

DOI: 10.1007/s11427-024-2790-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science China Life Sciences, 2025. Verfasst von Shan Lu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University Health Science Center; Department of Cardiology and Institu…. Hauptthemen laut MEDLINE: Signal Transduction, Janus Kinases, STAT Transcription Factors, Giant Cell Tumor of Tendon Sheath. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 82 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse-type tenosynovial giant cell tumor (dTGCT) is a destructive but rare benign proliferative synovial neoplasm. Although surgery is currently the main treatment modality for dTGCT, the recurrence risk is up to 50%. Therefore, there is a great need for effective drugs against dTGCT with minor side effects. The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling plays a central role in rheumatoid arthritis (RA), a disease with similar characteristics as dTGCT, but its function in dTGCT remains unknown. dTGCT fibroblast-like synoviocytes (FLS) and macrophages were isolated from 10 synovial tissue samples from dTGCT patients for the screening and validation of the five clinically approved JAK inhibitors to treat RA against dTGCT. Cell viability, cell death, inflammation and the activity of the JAK family members of cultured dTGCT FLS (both 2-D and 3-D) and macrophages were investigated for the efficacy of the JAK inhibitors. Here, we found that similar to RA, JAK/STAT signaling was markedly activated in the dTGCT synovium. Of the 5 JAK inhibitors, peficitinib was shown to have the most potency in addressing some of the pathological responses of dTGCT FLS and macrophages. The potency of peficitinib was much higher than pexidartinib, which is the only FDA-approved drug for dTGCT. Mechanistically, peficitinib inhibited tyrosine kinase 2 (TYK2), a JAK family member necessary for the pathological progression of dTGCT FLS and macrophages. In summary, we not only revealed JAK/STAT (especially TYK2) signaling as the major mechanism underlying dTGCT, but also identified peficitinib as a promising drug against dTGCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Signal TransductionJanus KinasesSTAT Transcription FactorsGiant Cell Tumor of Tendon SheathTYK2 KinaseAdamantaneNiacinamideHumansMacrophagesSynoviocytesJanus Kinase InhibitorsMaleArthritis, RheumatoidFemaleCell SurvivalSynovial Membrane

Stichwörter der Autor:innen

FLSJAK/STAT signalingTYK2dTGCTmacrophagespeficitinib

Substanzen

Janus KinasesSTAT Transcription FactorsTYK2 KinasepeficitinibAdamantaneNiacinamideTYK2 protein, humanJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Institute of Cardiovascular Sciences, School of Basic Medical Sciences, Peking University Health Science Center; Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; State Key L…
  • Department of Sports Medicine, Peking University Third Hospital, Institute of Sports Medicine of Peking University, Beijing, 100191, China.
  • Beijing Key Laboratory of Sports Injuries, Beijing, 100191, China.
  • Engineering Research Center of Sports Trauma Treatment Technology and Devices, Ministry of Education, Beijing, 100191, China.
  • State Key Laboratory of Membrane Biology, Institute of Molecular Medicine, College of Future Technology, Peking University, Beijing, 100871, China.
  • Peking University Health Science Centre, Peking University, Beijing, 100871, China.

Zitieren

APA

Lu, S., Cao, C., Zhang, W., Li, J., Yang, J., Huang, Z., Wu, Z., Liu, B., Huang, H., Wang, H., Wang, Y., Liu, D., Zhang, Z., Liu, K., Yang, G., Gong, X., Dai, H., Li, Y., Dong, E., …, & Zhang, Y. (2025). Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling. Science China Life Sciences. https://doi.org/10.1007/s11427-024-2790-7

Vancouver

Lu S, Cao C, Zhang W, Li J, Yang J, Huang Z, et al. Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling. Science China Life Sciences. 2025. doi:10.1007/s11427-024-2790-7

BibTeX
@article{Lu2025,
  author = {Lu, Shan and Cao, Chenxi and Zhang, Wenjia and Li, Jiayi and Yang, Jingli and Huang, Zisheng and Wu, Zhijun and Liu, Baitao and Huang, Hongjie and Wang, Haijun and Wang, Yongjian and Liu, Dingge and Zhang, Zhihua and Liu, Kaiping and Yang, Gang and Gong, Xi and Dai, Hui and Li, Yingjia and Dong, Erdan and Zhang, Xin and Zhang, Yan},
  title = {Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling},
  journal = {Science China Life Sciences},
  year = {2025},
  doi = {10.1007/s11427-024-2790-7}
}
Kostenlos starten →